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Summary
Background Antibacterial resistant infections are rising continuously, resulting in increased morbidity and mortality 
worldwide. With no new antibiotic classes entering the market and the possibility of returning to the pre-antibiotic 
era, the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) was established to address this problem. 
We aimed to quantify the scale and scope of publicly funded antibacterial resistance research across JPIAMR countries 
and at the European Union (EU) level to identify gaps and future opportunities.
Methods We did a systematic observational analysis examining antibacterial resistance research funding. Databases 
of funding organisations across 19 countries and at EU level were systematically searched for publicly funded 
antibacterial resistance research from Jan 1, 2007, to Dec 31, 2013. We categorised studies on the basis of the JPIAMR 
strategic research agenda’s six priority topics (therapeutics, diagnostics, surveillance, transmission, environment, and 
interventions) and did an observational analysis. Only research funded by public funding bodies was collected and no 
private organisations were contacted for their investments. Projects in basic, applied, and clinical research, including 
epidemiological, public health, and veterinary research and trials were identiﬁ ed using keyword searches by 
organisations, and inclusion criteria were based on the JPIAMR strategic research agenda’s six priority topics, using 
project titles and abstracts as ﬁ lters.
Findings We identiﬁ ed 1243 antibacterial resistance research projects, with a total public investment of €1·3 billion across 
19 countries and at EU level, including public investment in the Innovative Medicines Initiative. Of the total amount 
invested in antibacterial resistance research across the time period, €646·6 million (49·5%) was invested at the national 
level and €659·2 million (50·5%) at the EU level. When projects were classiﬁ ed under the six priority topics we found that 
763 (63%) of 1208 projects funded at national level were within the area of therapeutics, versus 185 (15%) in transmission, 
131 (11%) in diagnostics, 53 (4%) in interventions, and only 37 (3%) in environment and 39 (3%) in surveillance.
Interpretation This was the ﬁ rst systematic analysis of research funding of antibacterial resistance of this scale and 
scope, which relied on the availability and accuracy of data from organisations included. Large variation was seen 
between countries both in terms of number of projects and associated investment and across the six priority topics. 
To determine the future direction of JPIAMR countries a clear picture of the funding landscape across Europe and 
Canada is needed. Countries should work together to increase the eﬀ ect of research funding by strengthening national 
and international coordination and collaborations, harmonising research activities, and collectively pooling resources 
to fund multidisciplinary projects. The JPIAMR have developed a publicly available database to document the 
antibacterial resistance research collected and can be used as a baseline to analyse funding from 2014 onwards.
Funding JPIAMR and the European Commission.
Copyright © Kelly et al. Open Access article distributed under the terms of CC BY.
Introduction
Over the past decade the emerging global threat of 
antibacterial resistance has alarmingly come to the 
forefront. Antibiotics, thought one of the greatest medical 
discoveries of the 20th century, and still pivotal in 
medicine now, are becoming increasingly compromised. 
The diminishing eﬀ ectiveness of many antibiotics is due 
to the emergence of antibacterial resistance, and although 
a natural phenomenon, the inappropriate use of 
antibiotics in both human beings and animals worldwide, 
has accelerated the emergence and spread of highly 
resistant bacterial clones.1,2 As regularly highlighted, 
between 1929 and the 1970s, 20 new classes of antibiotics 
were introduced to the market; since then, there has been 
a discovery void, with only two new classes reaching this 
stage.3 The speed at which bacteria have evolved to 
become resistant to antibiotics has surpassed the speed of 
drug discovery. This exacerbates the issue of resistance 
and stresses the need to preserve the eﬃ  cacy of existing 
antibiotics. In short, without eﬀ ective treatment, not only 
would bacterial epidemics become a substantial public 
health threat once again, but advances in modern 
medicine, ranging from minor surgery to cancer therapy, 
would also be jeopardised.3
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In Europe alone, an estimated 25 000 people died from 
resistant bacterial sepsis in 2007, costing €1·5 billion, 
placing a substantial strain on already stressed health 
budgets.4 A review5 in 2014 estimated that an additional 
10 million lives a year will be lost by 2050 worldwide as a 
result of antimicrobial resistance in six key pathogens, 
four being bacterial, resulting in a cumulative cost of 
US$100 trillion. Because of the assumptions made and 
data analysed, these ﬁ gures are predicted to be an under-
estimate,5,6 but the trends are clear and cannot be ignored.
We are rapidly returning to a pre-antibiotic era, 
potentially resulting in the next world health crisis. The 
pressing urgency of this issue has been pointed out by 
several organisations worldwide, including WHO, with 
Research in context
Evidence before the study
On Jan 5, 2015, we searched PubMed and Google using the 
following search terms: “antibiotic research funding”, 
“antibiotic resistance research funding”, “antimicrobial research 
funding”, “antimicrobial resistance research funding”, 
“antibacterial resistance research funding”, “antibacterial 
research funding”, “AMR funding”, “infection research funding”, 
“bacteriology research funding”, for manuscripts published 
between Jan 1, 1995, and Jan 5, 2015, with no language 
restrictions. Our search identiﬁ ed two studies with some 
relevance to this study. Many reports and papers exist detailing 
the threat of antibacterial resistance; however, what research 
had been funded to address this pressing public health issue 
within and between countries was unknown. We concluded 
that the scale and scope of the two similar studies identiﬁ ed 
investigating the UK (Head and colleagues, 2014, and 
Bragginton and Piddock, 2014) were limited, only taking the UK 
into account, and their inclusion criteria did not span the 
breadth of our work. The Joint Programme–Neurodegenerative 
Disease initiative did a similar mapping exercise in 2011, which 
we took into consideration when designing this study (Joint 
Programme–Neurodegenerative Disease Mapping Exercise 
Report, 2011). Since we did not identify any similar exercise in 
antibacterial resistance, we did a comprehensive analysis to 
identify all the research funded across 19 Joint Programming 
Initiative on Antimicrobial Resistance (JPIAMR) countries and 
European Union (EU)-level organisations (Directorate General 
for Research and Innovation [DG Research], European Centre for 
Disease Prevention and Control [ECDC], Directorate General for 
Health and Consumer Aﬀ airs [DG-SANCO], and Innovative 
Medicines Initiative) related to antibacterial resistance from 
2007 to 2013 to have the evidence base to inﬂ uence future 
work. The JPIAMR strategic research agenda provided details on 
the six priority topics into which the research projects were 
categorised to produce meaningful results.
Added value of this study
This study takes a widely holistic and encompassing approach 
to look at a range of research areas that the JPIAMR strategic 
research agenda has identiﬁ ed as priorities to tackle the global 
problem of antibacterial resistance. We included research into 
treatments and preventive measures in human and veterinary 
medicine, diagnostics, surveillance, transmission, and 
interventions to prevent resistance emergence, acquisition, 
transmission, and infection. Additionally, this study analysed 
data from 19 countries (17 European countries, Canada, and 
Israel) and the EU, including DG Research (Framework 
Programme 6 and 7, European Research Council, and Innovative 
Medicines Initiative), DG-SANCO, and the ECDC. Hence, this 
study was the ﬁ rst comprehensive systematic analysis of 
research speciﬁ cally relevant to antibacterial resistance. By 
including veterinary, public health, infection control, and 
diagnostic research in our study, we are better able to deﬁ ne the 
scale and scope of research to reduce the burden of antibacterial 
resistance at a national level across 19 JPIAMR countries and at 
the EU level through the European Commission and related EU 
agencies. Results for the UK were compared with Head and 
colleagues, 2014, and Bragginton and Piddock, 2014, who also 
analysed UK data. However, their inclusion criteria did not span 
the breadth of this study (since we also included measures to 
prevent antibacterial resistance, optimisation of the use of 
existing antibiotics, diagnostics, surveillance, veterinary and 
environmental research, and interventions). Additionally, data 
for this study were mainly extracted through internal databases, 
probably resulting in more hits than manual searching through 
websites as was done for the two UK studies.
Implications of all the available evidence
Both UK-based studies and several other reports have claimed 
investment in antibacterial resistance research is inadequate 
when compared with the burden of resistance or investment in 
other areas of health research. We too came to the same 
conclusions; however, although the provision of new funds is 
necessary, what these studies did not address is that the burden 
of antibacterial resistance cannot be tackled by focusing solely 
on antibiotic development research. To overcome this global 
threat, a multidisciplinary and transnational approach is needed 
and all priorities identiﬁ ed by the JPIAMR strategic research 
agenda require due consideration and investment. Overall, our 
results provide a baseline from which JPIAMR countries and the 
EU-level organisations can measure their investment in this 
area from 2013 onwards and could provide the evidence needed 
to inﬂ uence practice and policy at the national level and EU 
level. This comprehensive analysis also lays the groundwork for 
future follow-on studies in the area to capture the number of 
new initiatives in antibacterial resistance in recent times, such 
as the UK antimicrobial resistance cross-council initiative and 
the diagnostic prizes announced by the UK and the European 
Commission, among others. The database of funded research 
on antibacterial resistance being created and maintained by the 
JPIAMR will help facilitate studies on antibacterial resistance 
more readily in the future.
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the poignant slogan used on World Health Day 2011, “No 
action today—no cure tomorrow”.7
Antibacterial resistance is a multifaceted problem 
needing vast and versatile solutions. No individual sector 
or nation has the capacity to independently handle this 
major societal challenge. Therefore, to collectively address 
antibacterial resistance at a national level and to increase 
the current impact of public research through more 
eﬀ ective, eﬃ  cient, and aligned investment, the Joint 
Programming Initiative on Antimicrobial Resistance 
(JPIAMR) was established in 2011.8 This initiative brings 
together 19 JPIAMR member countries, consisting of 
17 European countries (Belgium, Czech Republic, 
Denmark, Finland, France, Germany, Greece, Italy, the 
Netherlands, Norway, Poland, Romania, Spain, Sweden, 
Switzerland, Turkey, the UK), Canada, and Israel, with 
Estonia and Argentina as JPIAMR observers.
The JPIAMR launched its strategic research agenda in 
April, 2014, outlining the member states’ common vision 
to tackle antibacterial resistance.8 To ensure com-
prehensive actions are pursued, the strategic research 
agenda identiﬁ es six holistic and encompassing priority 
topics. The strategic research agenda acts as a dynamic 
framework on which the JPIAMR will continue to launch 
joint activities to guide and align research and investment 
to reduce the burden of antibacterial resistance across 
Europe and beyond. The JPIAMR will maintain and 
extend engagement activities internationally with 
diﬀ erent stakeholders, including industry, health service 
organisations, policy makers, the European Commission, 
and the research community, among others.
To guide future research activities and underpin the 
implementation of the JPIAMR strategic research 
agenda, an understanding of the present research 
landscape is necessary, which can be achieved by 
obtaining an objective insight into the scale and scope of 
research speciﬁ cally relevant to antibacterial resistance 
across JPIAMR countries, the European Commission, 
and related European Union (EU) agencies. No detailed 
analyses on research portfolios and associated investment 
to address antibacterial resistance—including human, 
veterinary, and environmental research—across multiple 
countries have been done previously. In this Article we 
present in-depth analyses examining research speciﬁ cally 
relevant to antibacterial resistance from major funding 
organisations funded within a 7 year period (2007–13) 
across the 19 JPIAMR countries and at EU level. The 
EU-level funding includes funding from the Directorate 
General for Research and Innovation (DG Research) 
through Framework Programme (FP) 6 and FP7 
(including the Innovative Medicines Initiative ﬁ rst 
programme [IMI-1] and the European Research Council 
[ERC]), the Directorate General for Health and Consumer 
Aﬀ airs (DG-SANCO), and the European Centre for 
Disease Prevention and Control (ECDC). We will then 
provide recommendations for how JPIAMR and member 
countries could proceed in the future.
Methods
Participating countries and data sources
We did a systematic observational analysis surveying the 
19 JPIAMR countries to establish levels of publicly 
funded research into antibacterial resistance. A 
questionnaire was sent to, and completed by, all JPIAMR 
national representatives who contacted suitable public 
funding agencies within their respective country. The full 
list of funding agencies included in this survey and the 
questionnaire used are in the appendix. All national 
representatives were briefed on the survey through 
presentations and discussions at JPIAMR meetings and 
through one-to-one communications with the data 
analyser. The variables collected included organisation 
name, principal investigator, lead institution, title, 
abstract or summary, start and end dates, and the total 
investment in euros. Only research funded by public 
funding bodies (which can invest in both public and 
private organisations) was collected and no private 
organisations were contacted for their investments 
because of diﬃ  culties in obtaining data. Data were also 
provided by DG Research (including FP6, FP7, ERC, and 
IMI), DG-SANCO, and ECDC, hereby collectively 
referred to as EU level. Additional desk study was done, 
mainly using websites and published databases from 
research organisations, at national and EU level, to 
identify through keyword searches additional publicly 
funded research that might have been missed. These 
projects were then veriﬁ ed for inclusion by the 
organisation or national representative. The data 
collected were the most comprehensive data available at 
the time of the survey from the organisations contacted.
We used the title and abstract where available 
(an abstract or summary was available for 984 [87%] of 
the 1129 JPIAMR country-level and 112 [98%] of the 
114 EU-level projects) as a ﬁ lter to establish research 
speciﬁ cally relevant to antibacterial resistance. The 
inclusion criteria were based on the six encompassing 
priority topics identiﬁ ed in the JPIAMR strategic research 
agenda. This Article concentrates on all active and 
completed research projects with committed funding of 
€100 000 or more from January, 2007, up to, and 
including, December, 2013, in basic, applied, and clinical 
research, including trials, epidemiological, public health, 
and veterinary research. Some projects might not have 
begun spending until early 2014 and projects less than 
€100 000 were not regarded by funders as research 
projects but as network funding and therefore were not 
captured for this Article. Projects included were in the 
areas of therapeutics, such as from basic research to 
market, ranging from understanding the molecular 
mechanisms of resistance, to the development of new 
antibiotics and therapeutic alternatives to antibiotics 
(such as antivirulence drugs, vaccines, coatings on 
implants, bacteriophages, drug delivery, etc), and the 
optimisation of the use of existing antibiotics 
(eg, stewardship and clinical trials on combination 
See Online for appendix
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treatment options); development of new diagnostics, 
such as a point-of-care test to eﬀ ectively diﬀ erentiate 
between bacterial and viral infections, or a rapid test to 
identify resistant bacteria and its resistance or sensitivity 
proﬁ le; surveillance, such as monitoring resistance rates, 
or anti biotic use in human or agricultural settings at local, 
national, or international levels; the transmission 
dynamics of resistance between diﬀ erent (human and 
animal) reservoirs; the assessment of the eﬀ ect of environ-
mental pollution (eg, water, soil, sewage) containing 
antibiotics, antibiotic residues, and resistant bacteria on 
the spread of resistance; and interventions to prevent 
the acquisition, transmission, and infection caused by 
antibacterial resistant bacteria (eg, infection control 
procedures, hospital layout, and education programmes).
Since funding mechanisms across diﬀ erent countries 
and agencies vary and to maximise consistency, invest-
ment allocated to infrastructure (eg, buildings, faculties, 
and networks) was not included, unless embedded 
within large grants.
All ﬁ nancial information is as reported by the funders; 
grants awarded in a currency other than euros were 
converted to euros by the organisations at the time of data 
collection. No adjustments were made by the data analyst 
for inﬂ ation since information about whether adjustments 
for inﬂ ation had been previously made by individual 
organisations was not available before submission.
Statistical analysis
To ensure the data collected met the established inclusion 
criteria, that no duplication of projects occurred, and that 
the data provided were complete and accurate, all data 
were checked and validated twice. First, this was done by 
the representatives within each participating JPIAMR 
country and EU-level organisations, and second, in more 
detail, by the data analyser to ensure consistency across 
funding organisations. For projects where only a 
proportion of the project met the inclusion criteria, for 
example a project looking at fungal and bacterial 
resistance, only a proportion of funding was allocated to 
this project; this was done on a case-by-case basis by the 
data analyser. To ensure consistent classiﬁ cation of 
projects, the data analyser read the title, abstract, and any 
further information of each individual project and 
classiﬁ ed them into one or more of the six priority topics. 
The JPIAMR Scientiﬁ c Advisory Board was consulted for 
any uncertainties.
Data were sourced, categorised, and analysed during 
the period of July 1, 2013, to Feb 1, 2015. Data analyses 
and generation of ﬁ gures and graphs were done with 
Microsoft Excel 2010.
Role of the funding source
The funders of the study had no role in the study design, 
data analysis, data interpretation, or writing of the 
Article. Members of the JPIAMR and the European 
Commission provided data included in this work. To the 
authors’ knowledge, all data analysed for this Article 
are already publicly available and therefore have no 
restrictions. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
We identiﬁ ed 1234 publicly funded antibacterial 
resistance projects across 19 JPIAMR countries and at 
the EU level, with a total investment of €960·7 million. 
Additionally, DG Research invested in another nine 
antibacterial resistance research projects via the IMI-1 
programme in partnership with the European Federation 
of Pharmaceutical Industries and Associations, bringing 
Therapeutics
763 (63%),
€428 199 158 (66%)
Diagnostics 
131 (11%),
€90 353 417 (14%)
Surveillance 
39 (3%),
€25 132 687 (4%)
Transmission
185 (15%),
€55 472 943 (9%)
Environment
 37 (3%),
€12 515  739 (2%)
Interventions 
53 (4%),
€34 972 596 (5%) 
Figure 1: Antibacterial resistance projects funded at national level between 
2007 and 2013 by priority topic with total funding
Proportions of pie chart represent number of projects by priority topic and not 
total funding. Projects funded at the European Union level are not included. 
Some projects are classiﬁ ed under more than one priority topic; hence, the 
numbers of projects are duplicated. Investment is not duplicated because a 
percentage of investment has been assigned to each priority topic in projects 
classiﬁ ed under more than one priority topic. Percentages do not add up to 
100% because of rounding.
Total number 
of projects, 
2007–13
Total funding 
(€), 2007–13
Proportion of total 
funding (excluding 
EC contribution to 
IMI)
Proportion of 
total funding
19 JPIAMR countries 1129 646 646 541 67·3% 49·5%
EU level* 114 659 201 418 NA 50·5%
EU level (excluding IMI) 105 314 072 980 32·7% 24·1%
IMI (EC contribution only) 9 345 128 438 NA 26·4%
Overall† 1243 1 305 847 959 100% 100%
The EU-level funding includes funding from the Director General for Research and Innovation (Framework 
Programme 6 and 7, including the IMI ﬁ rst programme and the European Research Council), the Directorate General 
for Health and Consumer Aﬀ airs, and the European Centre for Disease Prevention and Control from 2007 to 2013. 
JPIAMR=Joint Programming Initiative on Antimicrobial Resistance. EU=European Union. EC=European Commission. 
IMI=Innovative Medicines Initiative. NA=not applicable. *Sum total of EU level (excluding IMI) and IMI 
(EC contribution only) funding. †Sum total of 19 JPIAMR countries and EU level funding.
Table: Total committed public funding to antibacterial resistance research by JPIAMR countries and the EU
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the total public investment in antibacterial resistance 
research from 2007 to 2013 across 1243 projects to more 
than €1·3 billion (table). We found the 19 JPIAMR 
countries collectively contributed €646·6 million (67%) 
of the €960·7 million total investment in anti-
bacterial resistance research, whereas the remaining 
€314·1 million (33%) was provided at the EU level. 
However, when DG Research’s contribution to the IMI-1 
is considered, JPIAMR countries accounted for only 
49·5% (€646·6 million of €1·3 billion) of this investment 
and 50·5% (€659·2 million of €1·3 billion) was provided 
at the EU level (table). We investigated patterns over time 
by analysing the committed budget per year in 19 JPIAMR 
countries collectively and in EU-level organi sations, 
where positive patterns in funding from 2007 to 2013 
were observed (appendix).
At the national level, we identiﬁ ed 1129 projects funded 
across 19 JPIAMR countries, with a total public sector 
investment of €646·6 million across the 7 year period 
(2007–13). Most public sector funding went to 
universities, some went to hospitals, and only a small 
proportion went to private organisations.
We analysed the total number of projects and associated 
investment within each of the strategic research agenda 
priority topics and between countries. Because anti-
bacterial resistance is a complex issue, some multi-
disciplinary projects spanned more than one priority topic. 
As such, 69 (6·1%) of the 1129 projects in total funded at 
national level are classiﬁ ed under more than one priority 
topic, slightly inﬂ ating the total number of projects to 1208. 
Overlap was most evident between therapeutics and 
transmission in basic underpinning science projects and 
between transmission, environment, and surveillance. No 
duplication of funding occurred since an equal proportion 
of investment was assigned to each priority topic in 
projects classiﬁ ed under more than one priority topic.
Of 1208 projects investigated, with €646·6 million 
invested overall, 763 (63%) were within the area of 
therapeutics, with a total investment of €428·2 million 
(66%); 185 (15%) were based on the transmission of 
antibacterial resistance, with a total investment of 
€55·5 million (9%); 131 (11%) were about the development 
of new diagnostics, with a total investment of 
€90·4 million (14%); 53 (4%) were within the area of 
interventions, with a total investment of €35 million 
(5%); 39 (3%) were within the area of surveillance, with a 
total investment of €25·1 million (4%); and 37 (3%) 
focused on the environment, with a total investment of 
€12·5 million (2%; ﬁ gure 1).
We identiﬁ ed substantial variations in funding across 
countries at the national level, both in terms of number of 
projects and investment. Figure 2 shows the number of 
projects per country by priority topic; similar results were 
evident for investment (appendix). In an attempt to gauge 
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Figure 2: Total number of projects per country by priority topic funded at national level
Totals include national data from participating countries from 2007 to 2013 and do not include projects funded at the European Union level within these countries. 
Some projects are classiﬁ ed under more than one priority topic (hence, the numbers of projects are duplicated).
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the number of projects in this area per person of 
population, we also analysed the ratio of the number of 
projects to the population of that country (ﬁ gure 3). The 
mean country population from 2007 to 2013 was used.9,10 
Again, substantial variation existed between countries in 
the number of projects per person of the population with a 
broad spread around the mean, but the data suggested that 
Denmark, Estonia, Finland, the Netherlands, Sweden, and 
the UK funded more projects than the other countries 
included (ﬁ gure 3). Similar results were evident for the 
ratio of investment per person of the population (appendix).
We found that EU-level organisations invested 
€314·1 million in 105 research projects speciﬁ cally related 
to antibacterial resistance from 2007 to 2013 via DG 
Research (FP6, FP7, ERC), DG-SANCO, and ECDC (DG 
Research’s contribution to IMI is not shown). Since 
substantial investment was made through large 
multinational consortia, 19 (18%) of the 105 projects were 
classiﬁ ed under more than one priority topic. No 
duplication of funding occurred since a percentage of 
investment has been assigned to each priority topic in 
projects classiﬁ ed under more than one priority topic.
Of the 133 projects funded at the EU level (105 projects 
plus the duplicates), receiving an investment of 
€314·1 million overall, 71 (53%) were in the area of 
therapeutics, with a total investment of €197·4 million 
(63%); 18 (14%) were classiﬁ ed as transmission and 
received an investment of €42·7 million (13%); 16 (12%) 
were classiﬁ ed as surveillance, but only received an 
investment of €8·5 million (3%); 13 (10%) were classiﬁ ed 
as diagnostics and received €38·3 million (12%); 11 (8%) 
were classiﬁ ed as interventions, with investments of 
€21·2 million (7%); and four (3%) were classiﬁ ed as the 
environment, with investments of €5·9 million (2%; 
ﬁ gure 4).
Therapeutics
71 (53%),
€197 432 615 (63%)
Diagnostics
13 (10%),
€38 266 222 (12%)
Surveillance
16 (12%),
€8 517 341 (3%)
Transmission
18 (14%),
€42 683 210 (13%)
Environment
4 (3%),
€5 943 072 (2%)
Interventions
11 (8%),
€21 230 520 (7%)
Figure 4: Antibacterial resistance projects funded at the European Union 
level between 2007 and 2013 by priority topic with total funding
Proportions of pie chart represent number of projects by priority topic and not 
total funding. European Union level funding collectively refers to funding by the 
Director General for Research and Innovation (Framework Programme 6 and 
7 and the European Research Council), the Directorate General for Health and 
Consumer Aﬀ airs, and the European Centre for Disease Prevention and Control; 
Director General for Research and Innovation’s contribution to Innovative 
Medicines Initiative ﬁ rst programme is not included in this chart. Some projects 
are classiﬁ ed under more than one priority topic; as such, the numbers of 
projects are duplicated. Investment is not duplicated within the priority topics 
because a percentage of investment has been assigned to each priority topic in 
projects classiﬁ ed under more than one priority topic.
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Figure 3: Ratio of total number of projects per country to the total national population in millions
Total number of project includes national data from participating countries from 2007 to 2013 and does not include projects funded at European Union level. 
The mean country population from 2007 to 2013 was used.9,10 The mean ratio is shown by the dotted line.
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We captured nine projects within IMI-1 meeting the 
study inclusion criteria, with a total investment of 
€723·5 million. DG Research has committed 
€345·1 million to these nine projects via FP7. Most 
projects address more than one JPIAMR priority topic, 
although funding is mainly within priority topic A: 
therapeutics, to strengthen clinical research on anti-
bacterial resistance in Europe. In addition to preclinical 
and clinical research, the IMI-1 funded projects also 
focus on developing research infrastructure—for 
example, all projects, with the exception of one, are 
required to submit information to a speciﬁ c database, 
and three projects aim to develop a drug discovery 
platform and pan-European clinical trials and laboratory 
networks.
Discussion
To our knowledge, this study is the ﬁ rst systematic 
analysis of research funding speciﬁ cally relevant to 
antibacterial resistance across 19 countries, and at EU 
level, including the IMI-1. This study was also the ﬁ rst, to 
our knowledge, to take human, veterinary, and environ-
mental research, and all areas identiﬁ ed in the JPIAMR 
strategic research agenda, including therapeutics, 
diagnostics, surveillance, transmission, environ ment, 
and interventions, into account. IMI-1, the world’s largest 
public–private partnership in life sciences, involving 
the European Commission and European Federation 
of Pharmaceutical Industries and Associations, was 
important to capture as the programme is investing 
substantially to accelerate the development of better and 
safer medicines for patients, including antibiotics and 
alternative treatments for bacterial infections.11
When looking at the total spend and number of awards 
made in antibacterial resistance research from 2007 to 
2013, investment across the JPIAMR countries seems to 
be substantial. However, when compared with total 
spend on research across the disciplines, the amount 
spent on antibacterial resistance seems to be very small. 
For example, in the UK, one of the biggest investors, 
antibacterial resistance research spend was about 1% of 
the total research spend for the same period for the 
four research councils included.12–22 Also evident from the 
analyses of available data is that, at the EU level, 
substantially more was invested in antibacterial 
resistance research in 2007–13 (€314 million and an 
additional €345 million in IMI-1) than by the JPIAMR 
countries, which collectively invested €647 million. 
Therefore, not taking into account the DG Research’s 
contribution to the IMI-1, 33% of the total investment 
was at the EU level versus 67% from all 19 countries 
(table). By contrast, when looking at other major societal 
challenges, such as neurodegenerative diseases, the 
proportion of annual funding allocated in projects active 
on Jan 1, 2011, by DG Research (FP7) was 15% 
(€57 million) versus 85% (€314 million) by the 
20 countries participating in the Joint Programme for 
Neurodegenerative Disease.23 This proportion of funding 
invested in neurodegenerative disease research by DG 
Research is more in line with the EU research FP spend. 
As in 2007–08, EU FP funds represented about 7·5% of 
all civil research and development expenditure ﬁ nanced 
by governments of EU member states and European Free 
Trade Association countries. Although we recognise the 
7·5% captures all civil research and development spend, 
comparing it with what we found (33% funded at the EU 
level vs 67% by governments in antibacterial resistance 
research; table) emphasises the need for national budgets 
to redress the balance.24
Furthermore, countries varied substantially in terms of 
total number of antibacterial resistance projects funded 
(ﬁ gure 2) and number of projects funded per person of 
population (ﬁ gure 3), with Denmark, Estonia, Finland, 
the Netherland, Sweden, and the UK investing in a 
greater number of projects than the other countries 
investigated. Interestingly, those countries that invest the 
most have lower levels of antibacterial resistance than 
many of the countries included in this Article that invest 
the least.25 Also, within countries, funding for other high 
priority health needs varied substantially—for example, 
according to the Joint Programme for Neurodegenerative 
Disease ﬁ ndings, Germany was the biggest funder of 
neuro degenerative disease research,23 yet, we found 
Germany was only a very minor funder of antibacterial 
resistance research. This disparity between funding 
stresses the need for new funds for antibacterial 
resistance within countries rather than redistributing 
funds from other essential areas of research. The exact 
reasons for the disparate funding within and between 
countries are unclear, but we believe they argue for 
improved coordination between countries to share best 
practice and experience and to embark on joint research 
projects. We also believe these observations argue for 
greater sharing of results and data so that the outputs 
and eﬀ ects of large investments can be realised across 
the EU and beyond.
The burden of disease caused by antibacterial resistance 
is on the increase. In 2007, 25 000 people died in Europe 
from resistant bacterial sepsis, costing €1·5 billion.4 The 
2014 review from the O’Neill commission5 established by 
the UK Government estimated that an additional 
10 million lives per year will be lost by 2050 globally as a 
result of antimicrobial resistance in six key pathogens, 
resulting in a cumulative cost of US$100 trillion. This 
impending health challenge clearly needs to be addressed 
through research, but this research also needs to extend 
beyond the boundaries of individual states. The number 
of projects funded by individual states is high; 1129 (91%) 
of the 1243 projects identiﬁ ed in this survey were funded 
at the national level, but they only account for 
€646·6 million (49%) of the total investment, suggesting 
that these are relatively small awards and highly focused. 
These awards would certainly have been made on the 
basis of scientiﬁ c excellence through normal schemes.
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In view of the relatively small amount of funds invested 
at the national level in antibacterial resistance compared 
with the EU level, other health priorities, and other 
countries, changes might now be needed at the national 
level in countries that correspond with the strategic 
importance and growth of antibacterial resistance. The 
idea behind joint programming is that resources are 
scarce and the availability of public investments in 
research has limits.26 Hence, participating countries will 
not only need to close the gap between the health 
research needs and the actual research funded but also 
make strategic and coordinated investments with existing 
and new funds. These strategies entail that countries 
work both alone and together in a more eﬃ  cient way 
than they are now to increase the eﬀ ectiveness of 
research through strengthening national and inter-
national coordination and collaborations, harmonising 
research activities, and collectively pooling resources. 
From our analysis, some countries already invest 
substantial funds into antibacterial resistance but a new 
way of funding multidisciplinary and transnational 
antibacterial resistance research is needed. The UK Cross 
Research Council Initiative aims to achieve this goal, 
not only by linking diﬀ erent research disciplines, both 
nationally and internationally, but also through 
coordination of diﬀ erent sectors and funders through the 
UK antimicrobial resistance funders forum.27,28
The JPIAMR has also developed the strategic research 
agenda to coordinate research in close collaboration 
with the funding instruments of the European 
Commission, speciﬁ cally Horizon 2020, IMI, and the 
ERA-NET scheme to increase eﬀ ectiveness and avoid 
duplication. Countries could use the JPIAMR strategic 
research agenda now as a template for coordination. 
Beyond Europe, government priorities are beginning to 
change, and new increased budget commitments are 
being discussed, with the US Government proposing to 
invest more than $1·2 billion of funding for 2016 to 
improve antibiotic stewardship, strengthen antibiotic 
resistance risk assessment, surveillance, and reporting 
capabilities, and drive research and innovation in the 
human health and agricultural sectors.29 Activity within 
the area of diagnostics has also increased, with the US 
Department of Health and Human Services announcing 
a diagnostic prize of up to $20 million,30 the European 
Commission announcing a €1 million diagnostic prize,31 
and the UK announcing a £10 million Longitude prize 
in diagnostics.32
As with similar exercises,33,34 the data presented have 
limitations. To ensure the information captured was 
comparable and consistent, only research projects were 
captured, and institutional funding was unobtainable. 
Additionally, because the remit of the study was to 
capture research projects only, surveillance systems 
that are now core programmes—such as ECDC 
in-house programmes and national surveillance 
programmes, including the German KISS and the 
French RAISIN programmes, among others—were not 
captured in this study and therefore the picture of 
surveillance funding captured by this study is not 
comprehensive. We relied on the accuracy of the data 
provided by funding bodies, although all data were 
veriﬁ ed by each national or EU representative and any 
apparent discrepancies or duplication of projects were 
dealt with by the data analyst. 
All projects were determined for inclusion, ﬁ rst, by 
each organisations representative, and second, by the 
data analyst. Some projects might have been missed 
because of the search terms used or the diﬃ  culties in 
accessing data in some countries. The rules regarding 
what a research grant will cover can vary between 
countries (eg, salary of investigators); we made no 
attempt to remove any indirect and estate costs included 
in the funding amounts and did not adjust for inﬂ ation. 
However, to deal with these ﬁ nancial confounders, we 
analysed the number of projects and compared trends 
across countries using number of projects rather than 
focusing solely on investment. If this exercise were to 
be extended globally and include countries such as 
China and India with ﬂ uctuating currency and inﬂ ation 
rates over time, the method described by Young and 
colleagues35 could be followed to ensure careful 
comparison between countries with variable exchange 
and inﬂ ation rates. The subjective classiﬁ cation of these 
cross-disciplinary projects, by the data analyst, to one or 
more of the priority topics leaves the exercise somewhat 
open to question. Additionally, for projects classiﬁ ed 
under more than one priority topic, we could not 
ascertain the exact proportion of grant funding to be 
allocated to each of the topics, hence, to ensure 
consistency an equal proportion of funding was 
assigned to each. Overlap was often evident between 
therapeutics and transmission in basic underpinning 
science projects and also between transmission, 
environment, and surveillance.
Currency conversions to euros will not be precise 
because of variations in the exchange rates across the 
data collection process. Although private funding 
invested in IMI-1 was available, this study did not include 
private sector funding because of diﬃ  culties in openly 
accessing private funding and project information 
beyond IMI-1.
As a result of this study, several recommendations 
have been made to the JPIAMR members to consider, 
with some activities already underway. At present, no 
comprehensive database exists to document research at 
both national and international levels, and, in view of 
this study, improvements in data sharing and 
communication clearly need to be achieved at the 
national level in several countries. The JPIAMR is 
actively working to improve data sharing and has turned 
the research data collected for this study into a useful, 
freely accessible, and searchable database available 
on the JPIAMR website. The database will enable 
For the JPIAMR website see 
http://www.jpiamr.eu/
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The substantial allocation of antibacterial resistance 
projects and investment within the area of therapeutics, 
both at the national and EU level, is probably because of 
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